Parkinsn's Email List Message

Posting to the Parkinsn List is a benefit of Subscription


[Message Prev][Message Next][Thread Prev][Thread Next][Message Index][Thread Index]

Re: Altered cells deliver Parkinson's therapy to brain

P-I-E-N-O News Discussion and Search

Google

Mail converted by MHonArc 2.6.10
Site Hosting donated by He.net
&
Grant from The Parkinson Alliance


The guy who cloned Dolly the sheep wants to go ahead with human trials on
people who are going to die soon anyway.  He thinks we will have to wait too
long if we don't
Ray
----- Original Message -----
From: "Inge Clody" <ingeclody@xxxxxxxx>
To: <PARKINSN@xxxxxxxxxxxxxxxxxxxx>
Sent: Wednesday, December 28, 2005 2:58 PM
Subject: Re: Altered cells deliver Parkinson's therapy to brain


THIS IS WONDERFUL NEWS
HOWEVER...........
HOW LONG WILL IT TAKE BEFORE IT IS FDA APPROVED?

On Wed, 28 Dec 2005 08:03:37 +0100 "M.Schild" <mmoo@xxxxxxxxxxxxxxxx>
writes:
Altered cells deliver Parkinson's therapy to brain
Tue Dec 27, 2005 7:17 PM GMT9

   NEW YORK (Reuters Health) - Genetically modified nerve
'progenitor' cells
can be used as mini-pumps to deliver nerve growth factor to the
brain, a new
study in animals shows.
 The results suggest such an approach could be used to treat
Parkinson's
disease and other brain diseases in humans, Dr. Clive D. Svendsen of
the
University of Wisconsin-Madison and colleagues report.
 A nerve growth factor called "glial cell line-derived neurotrophic
factor" (abbreviated to GDNF) has been shown to protect
dopamine-producing
neurons, which are lost in Parkinson's disease, Svendsen and his
team note in
the research journal Gene Therapy.
 In fact, it's safe to infuse GDNF into brain regions of patients
with
Parkinson's disease, according to some studies, and it seems
effective.
However, delivering the drug in this fashion is complex and only
reaches a
single point in the brain.
 In the current study, using rats with symptoms akin to Parkinson's
disease,
the researchers investigated the effect of human neural progenitor
cells
engineered to produce GDNF.
 The rats were transplanted with the modified cells, and after two
weeks these
were seen to have migrated to affected areas and to be secreting
enough GDNF
to extend the survival of dopamine neurons and promote outgrowth of
nerve
fibers.
 By five weeks post-transplant, the animals showed a "strong trend
toward
functional improvement," and at eight weeks the cells were still
releasing
the growth factor.
 Tests in elderly monkeys showed the cells survived and continued to
release
GDNF for three months after transplant. None of the animals in the
studies
developed brain tumors.
 Svendsen and his colleagues conclude that their results "show that
combining
human progenitor cell therapy with ... gene therapy is a powerful
approach to
the future treatment of Parkinson's disease and other neurological
conditions."
 SOURCE: Gene Therapy, online December 15, 2005.

----------------------------------------------------------------------
To sign-off Parkinsn send a message to:
mailto:listserv@xxxxxxxxxxxxxxxxxxxx
In the body of the message put: signoff parkinsn




Inge Clody
Minado, Reg.
www.flash.net/~minado1

----------------------------------------------------------------------
To sign-off Parkinsn send a message to:
mailto:listserv@xxxxxxxxxxxxxxxxxxxx
In the body of the message put: signoff parkinsn


---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:listserv@xxxxxxxxxxxxxxxxxxxx In the body of the message put: signoff parkinsn